X4 Pharmaceuticals (XFOR) Price to Earnings (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Price to Earnings for 8 consecutive years, with 36.52 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 6117.48% year-over-year to 36.52; the trailing twelve-month figure through Jun 2026 stood at 6.55 (down 4313.48% YoY), and the FY2025 full-year result was 2.14, up 36.12% from the prior year.
• Price to Earnings slipped to 36.52 in Q2 2026 per XFOR's latest filing, from 25.75 in the prior quarter.
• Across five years, Price to Earnings topped out at 148.75 in Q1 2025 and bottomed at 2336.61 in Q3 2023.
• Historically, Price to Earnings has averaged 181.4 across 5 years, with a median of 39.41 in 2022.
• The sharpest annual moves came in 2025 and 2026: Price to Earnings soared 192.39% in 2025, then sank 6117.48% in 2026.
• Over 5 years, Price to Earnings stood at 65.02 in 2022, then plunged by 259.59% to 233.81 in 2023, then jumped by 98.65% to 3.15 in 2024, then plunged by 124.66% to 7.07 in 2025, then plunged by 416.23% to 36.52 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 36.52, 25.75, and 7.07 for Q2 2026, Q1 2026, and Q4 2025 respectively.